Portfolio

Company Announcements

Notice of AGM

Related Companies

By LSE RNS

RNS Number : 1743S
Premaitha Health PLC
29 September 2017
 

Premaitha Health PLC

 

Notice of Annual General Meeting

 

Manchester, UK - 29 September 2017: Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing, announces that its annual general meeting will be held at 2:00 p.m. on 24 October 2017 at Greenheys Building, Manchester Science Park, Manchester M15 6JJ.

 

For more information, please contact:


Premaitha Health PLC
Dr Stephen Little, Chief Executive Officer

Barry Hextall, Chief Financial Officer

Joanne Cross, Head of Marketing

investors@premaitha.com

 

Tel: +44 (0)161 667 1053

 

Cairn Financial Advisers LLP (NOMAD)
Liam Murray / James Caithie

Tel: +44 (0)20 7213 0880

finnCap (Broker)

Adrian Hargrave / Scott Mathieson (Corporate Finance)

Tony Quirke (Corporate Broking)

Tel: +44 (0)20 7220 0500

Vigo Communications

Ben Simons / Fiona Henson / Antonia Pollock

premaitha@vigocomms.com

 

Tel: +44 (0)20 7830 9700

 

 

About Premaitha

 

Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group's primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market.

 

Premaitha's IONA® test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA® test is performed on a maternal blood sample - which contains traces of fetal DNA - and estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions.

 

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA® test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.

 

In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha's IONA® test. Yourgene brings significant benefits to the Group through expanded market access in Asia - the world's fastest growing NIPT market - as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.

 

Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.

 

 

 

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOASEDEFAFWSEDU

Top of Page